Eagle Pharmaceuticals Investor Update: Kaplan Fox & Kilsheimer LLP Notifies Eagle Pharmaceuticals Investors of a Class Action and Upcoming Deadline
December 13, 2023 12:30 ET
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox notifies investors of Class Action filed against Eagle Pharmaceuticals.
MDRX INVESTOR ALERT: Kaplan Fox & Kilsheimer LLP Reminds Veradigm Investors of a Class Action Lawsuit and Upcoming Deadline
December 09, 2023 08:02 ET
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox & Kilsheimer LLP reminds investors that a complaint has been filed on behalf of purchasers of the common stock of Veradigm Inc.
LIVEPERSON, INC. INVESTOR ALERT: Kaplan Fox & Kilsheimer LLP Notifies LivePerson Investors of a Class Action Lawsuit and Upcoming Deadline
December 08, 2023 14:30 ET
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox & Kilsheimer LLP reminds investors that a complaint has been filed on behalf of investors who purchased or otherwise acquired LivePerson, Inc.
VERADIGM SHAREHOLDER UPDATE: Kaplan Fox & Kilsheimer LLP Reminds Veradigm Investors of Upcoming Deadline
December 08, 2023 14:20 ET
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox & Kilsheimer LLP reminds investors that a complaint has been filed on behalf of purchasers of the common stock of Veradigm Inc.
CHPT Investor Alert: Kaplan Fox & Kilsheimer LLP Notifies ChargePoint Investors of a Class Action Lawsuit and Upcoming Deadline
December 07, 2023 08:00 ET
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox reminds investors that a complaint has been filed on behalf of investors that purchased or otherwise acquired ChargePoint Holdings, Inc.
EGRX Investor Alert: Kaplan Fox & Kilsheimer LLP Investigates Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX)
December 07, 2023 08:00 ET
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased securities of Eagle Pharmaceuticals, Inc.
SLRN Investor Alert: Kaplan Fox & Kilsheimer LLP Investigates Acelyrin, Inc. (Nasdaq: SLRN)
December 07, 2023 08:00 ET
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased Acelyrin, Inc.
VERADIGM INVESTOR ALERT: Kaplan Fox & Kilsheimer LLP Notifies Veradigm Investors of a Class Action Lawsuit and Upcoming Deadline
December 05, 2023 21:54 ET
|
Kaplan Fox & Kilsheimer LLP
NEW YORK, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP reminds investors that a complaint has been filed on behalf of purchasers of the common stock of Veradigm Inc. (“Veradigm”...
FISKER INVESTOR ALERT: Kaplan Fox & Kilsheimer LLP Notifies Fisker Investors of a Class Action Lawsuit and Upcoming Deadline
December 05, 2023 21:51 ET
|
Kaplan Fox & Kilsheimer LLP
NEW YORK, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP reminds investors that a complaint has been filed on behalf of investors that purchased or otherwise acquired the...
Kaplan Fox & Kilsheimer LLP Investigates Acelyrin, Inc. (Nasdaq: SLRN)
December 04, 2023 08:00 ET
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased Acelyrin, Inc.